Xconomy National

Archives

by in

Entry	Author	Date	Location
Genentech, ImmunoGen’s Souped-Up Antibody for Breast Cancer Passes Key Test	Luke Timmerman	09/24/11	San Francisco
Vertex Gets FDA OK, Alnylam Plans For ASCO, Biogen Drug Advances in Europe, & More Boston-Area Life Sciences News	Erin Kutz	05/27/11	Boston
ImmunoGen Grabs $84M	Luke Timmerman	05/20/11	Boston
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News	Erin Kutz	03/04/11	Boston
ImmunoGen CEO Highlights Two New Souped-Up Antibodies Against Cancer	Ryan McBride	02/25/11	Boston
Adriana Jenkins, Boston Biotech PR Maven, Dies from Breast Cancer at 41	Luke Timmerman	02/10/11	Boston
Alkermes Drug Approved for Opioid Addiction, Genzyme Faces Shareholder Lawsuits, NinePoint Gets $33M, & More Boston-Area Life Sciences News	Erin Kutz	10/15/10	Boston
ImmunoGen Inks $45M Deal With Novartis, Tata Leads $9.5M Sun Catalytix Deal, InfraReDx Gets $21M, & More Boston-Area Deals News	Erin Kutz	10/13/10	Boston
ImmunoGen Gets $45M Upfront From Novartis To Make Souped Up Antibodies For Cancer	Luke Timmerman	10/11/10	Boston
Genentech’s Souped-Up Breast Cancer Drug Beats Original Herceptin in Head-to-Head Study	Luke Timmerman	10/08/10	San Francisco
PerkinElmer Sells Unit for $500M, Aveo Stock Climbs, Pfizer Buys FoldRx, & More Boston-Area Life Sciences News	Erin Kutz	09/03/10	Boston
ImmunoGen and Genentech “Empowered Antibody” Cancer Drug Fails to Garner Accelerated Approval from FDA	Erin Kutz	08/27/10	Boston
Genentech Agrees to Pay Seattle Genetics Up to $900M for “Empowered Antibodies”	Luke Timmerman	08/03/10	Seattle
Genentech Seeks FDA Nod for T-DM1	Luke Timmerman	07/07/10	San Francisco
Genentech’s Souped-Up Herceptin: The Odyssey Toward a More Powerful Breast Cancer Drug	Luke Timmerman	06/14/10	San Francisco
Biogen CEO Retires, Genzyme Board Nominates Amgen Vet and Strikes Deal with Icahn, Xconomy Spotlights Life Sciences XSITE Speakers, & More Boston-Area Life Sciences News	Erin Kutz	06/11/10	Boston
XSITE’s Biotech Gurus to Cover the State of New England Biotech, the Return of Platforms	Luke Timmerman	06/07/10	Boston
Scripps Chemistry Idea “Clicks” With Big Pharma, Seattle’s Integrated Diagnostics	Luke Timmerman	05/19/10	San Diego
Oxford’s Fambrough Leaves for Dicerna, Clinical Data Aims to Take on Big Pharma with Antidepressants, Genzyme’s Termeer Courts Shareholders, & More Boston-Area Life Sciences News	Erin Kutz	05/14/10	Boston
ImmunoGen Raises $67M in Stock Deal	Luke Timmerman	05/06/10	Boston
Celldex CEO Treks From NJ to Massachusetts in Pursuit of Antibody Drugs for Cancer	Luke Timmerman	02/23/10	Boston
Seattle Genetics Maps Out a Future With Antibody Drugs That Are “Empowered”	Luke Timmerman	01/06/10	Seattle
Ambrx, Saying Thanks to its Rivals, Rides Wave of Interest in “Empowered” Antibodies	Luke Timmerman	01/06/10	San Diego
Biogen Idec Board in Flux, Cubist Acquires Calixa, ImmunoGen Drug Passes Clinical Test, & More Boston-Area Life Sciences News	Rebecca Zacks	12/16/09	Boston
Breast Cancer “Smart Bomb” Drug From Roche, ImmunoGen Passes Important Trial	Luke Timmerman	12/12/09	Boston
Breast Cancer “Smart Bomb” From Roche, ImmunoGen Shows Tumor Shrinkage in Big Test	Luke Timmerman	12/09/09	Boston
A Graceful Exit for Gloucester, Pink Slips at Sermo, A Half a Billion Bucks for Vertex, & More Boston-Area Life Sciences News	Rebecca Zacks	12/09/09	Boston
Supercharged Herceptin Nears Pivot Point, as ImmunoGen, Roche Await Data on Breast Cancer “Smart Bomb”	Luke Timmerman	12/07/09	Boston
Ironwood Pharma Eyes $172.5M IPO, Biogen CEO Pay Under Fire, & More Boston Life Sciences News	Ryan McBride	11/25/09	Boston
Metcalfe Reflects on $2.7B 3Com Buyout, MyPunchbowl Parent Adds New Punch, $30M More for Fate Therapeutics, & More Boston Deals News	Ryan McBride	11/20/09	Boston
Page 1 of 2	next page »